Cargando…

COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Huhn, Gregory, Poorbaugh, Josh, Zhang, Lin, Beasley, Stephanie, Nirula, Ajay, Brothers, Jennifer, Welbel, Sharon, Wilson, James, Gillani, Sheena, Weber, Kathleen M., Morack, Ralph, Keckler, Kody, Benschop, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462709/
https://www.ncbi.nlm.nih.gov/pubmed/36083883
http://dx.doi.org/10.1371/journal.pone.0273323
_version_ 1784787248068165632
author Huhn, Gregory
Poorbaugh, Josh
Zhang, Lin
Beasley, Stephanie
Nirula, Ajay
Brothers, Jennifer
Welbel, Sharon
Wilson, James
Gillani, Sheena
Weber, Kathleen M.
Morack, Ralph
Keckler, Kody
Benschop, Robert J.
author_facet Huhn, Gregory
Poorbaugh, Josh
Zhang, Lin
Beasley, Stephanie
Nirula, Ajay
Brothers, Jennifer
Welbel, Sharon
Wilson, James
Gillani, Sheena
Weber, Kathleen M.
Morack, Ralph
Keckler, Kody
Benschop, Robert J.
author_sort Huhn, Gregory
collection PubMed
description BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. METHODS: Cook County Health employees provided blood samples and completed an online survey 8–10 weeks after a PCR-confirmed positive SARS-CoV-2 test (pre-vaccinated, N = 41) and again, 1–4 weeks after completion of a 2-dose series mRNA BNT162b2 COVID-19 vaccine (post-vaccinated, N = 27). Associations were evaluated between SARS-CoV-2 antibody titers, participant demographics, and clinical characteristics. Antibody titers and angiotensin-converting enzyme 2 (ACE2) neutralization were compared before and after the mRNA BNT162b2 COVID-19 vaccine. RESULTS: Antibody titers to the spike protein (ST4), receptor binding domain (RBD), and RBD mutant D614G were significantly associated with anosmia and ageusia, cough, and fever. Spike protein antibody titers and ACE2 neutralization were significantly higher in participants that presented with these symptoms. Antibody titers to the spike protein N-terminal domain (NTD), RBD, and ST4, and ACE2 IC50 were significantly higher in all post-vaccinated participant samples compared to pre-vaccinated participant sample, and not dependent on previously reported symptoms. CONCLUSIONS: Spike protein antibody titers and ACE2 neutralization are associated with the presentation of anosmia and ageusia, cough, and fever after SARS-CoV-2 infection. Symptom response to previous SARS-CoV-2 infection did not influence the antibody response from subsequent vaccination. These results suggest a relationship between infection severity and the magnitude of the immune response and provide meaningful insights into COVID-19 immunity according to discrete symptom presentation.
format Online
Article
Text
id pubmed-9462709
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-94627092022-09-10 COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine Huhn, Gregory Poorbaugh, Josh Zhang, Lin Beasley, Stephanie Nirula, Ajay Brothers, Jennifer Welbel, Sharon Wilson, James Gillani, Sheena Weber, Kathleen M. Morack, Ralph Keckler, Kody Benschop, Robert J. PLoS One Research Article BACKGROUND: The humoral response to SARS-CoV-2 can provide immunity and prevent reinfection. However, less is known about how the diversity, magnitude, and length of the antibody response after a primary infection is associated with symptoms, post-infection immunity, and post-vaccinated immunity. METHODS: Cook County Health employees provided blood samples and completed an online survey 8–10 weeks after a PCR-confirmed positive SARS-CoV-2 test (pre-vaccinated, N = 41) and again, 1–4 weeks after completion of a 2-dose series mRNA BNT162b2 COVID-19 vaccine (post-vaccinated, N = 27). Associations were evaluated between SARS-CoV-2 antibody titers, participant demographics, and clinical characteristics. Antibody titers and angiotensin-converting enzyme 2 (ACE2) neutralization were compared before and after the mRNA BNT162b2 COVID-19 vaccine. RESULTS: Antibody titers to the spike protein (ST4), receptor binding domain (RBD), and RBD mutant D614G were significantly associated with anosmia and ageusia, cough, and fever. Spike protein antibody titers and ACE2 neutralization were significantly higher in participants that presented with these symptoms. Antibody titers to the spike protein N-terminal domain (NTD), RBD, and ST4, and ACE2 IC50 were significantly higher in all post-vaccinated participant samples compared to pre-vaccinated participant sample, and not dependent on previously reported symptoms. CONCLUSIONS: Spike protein antibody titers and ACE2 neutralization are associated with the presentation of anosmia and ageusia, cough, and fever after SARS-CoV-2 infection. Symptom response to previous SARS-CoV-2 infection did not influence the antibody response from subsequent vaccination. These results suggest a relationship between infection severity and the magnitude of the immune response and provide meaningful insights into COVID-19 immunity according to discrete symptom presentation. Public Library of Science 2022-09-09 /pmc/articles/PMC9462709/ /pubmed/36083883 http://dx.doi.org/10.1371/journal.pone.0273323 Text en © 2022 Huhn et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Huhn, Gregory
Poorbaugh, Josh
Zhang, Lin
Beasley, Stephanie
Nirula, Ajay
Brothers, Jennifer
Welbel, Sharon
Wilson, James
Gillani, Sheena
Weber, Kathleen M.
Morack, Ralph
Keckler, Kody
Benschop, Robert J.
COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title_full COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title_fullStr COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title_full_unstemmed COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title_short COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine
title_sort covid-19 symptom relationship to antibody response and ace2 neutralization in recovered health systems employees before and after mrna bnt162b2 covid-19 vaccine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462709/
https://www.ncbi.nlm.nih.gov/pubmed/36083883
http://dx.doi.org/10.1371/journal.pone.0273323
work_keys_str_mv AT huhngregory covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT poorbaughjosh covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT zhanglin covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT beasleystephanie covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT nirulaajay covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT brothersjennifer covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT welbelsharon covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT wilsonjames covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT gillanisheena covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT weberkathleenm covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT morackralph covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT kecklerkody covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine
AT benschoprobertj covid19symptomrelationshiptoantibodyresponseandace2neutralizationinrecoveredhealthsystemsemployeesbeforeandaftermrnabnt162b2covid19vaccine